Bibliography
- Philip PA : Targeted therapies for pancreatic cancer.Gastrointest. Cancer Res.2(Suppl. 4), S16–S19 (2008).
- Shaib YH , DavilaJA, El-SeragHB: The epidemiology of pancreatic cancer in the United States: changes below the surface.Aliment Pharmacol. Ther.24(1), 87–94 (2006).
- Denekamp J : Endothelial cell proliferation as a novel approach to targeting tumour therapy.Br. J. Cancer45(1), 136–139 (1982).
- Vincent S , DePaceD, FinkelsteinS: Distribution of anionic sites on the capillary endothelium in an experimental brain tumor model.Microcirc Endothelium Lymphatics4(1), 45–67 (1988).
- Campbell RB , FukumuraD, BrownEBet al.: Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors.Cancer Res.62(23), 6831–6836 (2002).
- Thurston G , McLeanJW, RizenMet al.: Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice.J. Clin. Invest.101(7), 1401–1413 (1998).
- Campbell RB , YingB, KuestersGM, HemphillR: Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics.J. Pharm. Sci.98(2), 411–429 (2009).
- Schuch G : EndoTAG-1. MediGene.Curr. Opin. Investig. Drugs6(12), 1259–1265 (2005).
- Campbell RB : Tumor physiology and delivery of nanopharmaceuticals.Anticancer Agents Med. Chem.6(6), 503–512 (2006).
- Conejo JR , KleeffJ, KoliopanosAet al.: Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers.Int. J. Cancer88(1), 12–20 (2000).
- Kaji T , YamamotoC, Oh-iMet al.: The vascular endothelial growth factor VEGF165 induces perlecan synthesis via VEGF receptor-2 in cultured human brain microvascular endothelial cells.Biochim. Biophys. Acta1760(9), 1465–1474 (2006).
- Dabbas S , KaushikRR, DandamudiS, KuestersGM, CampbellRB: Importance of the liposomal cationic lipid content and type in tumor vascular targeting: physicochemical characterization and in vitro studies using human primary and transformed endothelial cells.Endothelium15(4), 189–201 (2008).
- Allen TM , HansenC, MartinF, RedemannC, Yau-YoungA: Liposomes containing synthetic lipid derivatives of poly (ethylene glycol) show prolonged circulation half-lives in vivo.Biochim. Biophys. Acta1066(1), 29–36 (1991).
- Dandamudi S , CampbellRB: Development and characterization of magnetic cationic liposomes for targeting tumor microvasculature.Biochim. Biophys. Acta1768(3), 427–438 (2007).
- Immordino ML , DosioF, CattelL: Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential.Int. J. Nanomedicine1(3), 297–315 (2006).
- Dandamudi S , CampbellRB: The drug loading, cytotoxicty and tumor vascular targeting characteristics of magnetite in magnetic drug targeting.Biomaterials28(31), 4673–4683 (2007).
- Folkman J : Tumor angiogenesis: therapeutic implications.N. Engl. J. Med.285(21), 1182–1186 (1971).
- Folkman J : Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis.N. Engl. J. Med.333(26), 1757–1763 (1995).
- Ferrara N : VEGF and the quest for tumour angiogenesis factors.Nat. Rev. Cancer2(10), 795–803 (2002).
- Ferrara N : Vascular endothelial growth factor: basic science and clinical progress.Endocr. Rev.25(4), 581–611 (2004).
- Pellet-Many C , FrankelP, JiaH, ZacharyI: Neuropilins: structure, function and role in disease.Biochem. J.411(2), 211–226 (2008).
- Ferrara N , HillanKJ, GerberHP, NovotnyW: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.Nat. Rev. Drug Discov.3(5), 391–400 (2004).
- Cohen MH , GootenbergJ, KeeganP, PazdurR: FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.Oncologist12(6), 713–718 (2007).
- Cohen MH , GootenbergJ, KeeganP, PazdurR: FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer.Oncologist12(3), 356–361 (2007).
- Gerber HP , FerraraN: Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies.Cancer Res.65(3), 671–680 (2005).
- Shih T , LindleyC: Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.Clin. Ther.28(11), 1779–1802 (2006).
- Sachdev JC , JahanzebM: Evolution of bevacizumab-based therapy in the management of breast cancer.Clin. Breast Cancer8(5), 402–410 (2008).
- Scheer MG , StollmanTH, BoermanOCet al.: Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: lack of correlation with VEGF-A expression.Eur. J. Cancer44(13), 1835–1840 (2008).
- Stollman TH , ScheerMG, FranssenGMet al.: Tumor accumulation of radiolabeled bevacizumab due to targeting of cell- and matrix-associated VEGF-A isoforms.Cancer Biother. Radiopharm.24(2), 195–200 (2009).
- Stollman TH , ScheerMG, LeendersWPet al.: Specific imaging of VEGF-A expression with radiolabeled anti-VEGF monoclonal antibody.Int. J. Cancer122(10), 2310–2314 (2008).
- Nagengast WB , de Vries EG, Hospers GA et al.: In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J. Nucl. Med.48(8), 1313–1319 (2007).
- Maruyama K , TakizawaT, YudaT, KennelSJ, HuangL, IwatsuruM: Targetability of novel immunoliposomes modified with amphipathic poly (ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies.Biochim. Biophys. Acta1234(1), 74–80 (1995).
- Pan X , WuG, YangW, BarthRF, TjarksW, LeeRJ: Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR.Bioconjug. Chem.18(1), 101–108 (2007).
- Park JW , HongK, KirpotinDBet al.: Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.Clin. Cancer Res.8(4), 1172–1181 (2002).
- Schnyder A , KrahenbuhlS, TorokM, DreweJ, HuwylerJ: Targeting of skeletal muscle in vitro using biotinylated immunoliposomes.Biochem. J.377(Pt 1), 61–67 (2004).
- Kirpotin D , ParkJW, HongKet al.: Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.Biochemistry36(1), 66–75 (1997).
- Ades EW , CandalFJ, SwerlickRAet al.: HMEC-1: establishment of an immortalized human microvascular endothelial cell line.J. Invest. Dermatol.99(6), 683–690 (1992).
- Skehan P , StorengR, ScudieroDet al.: New colorimetric cytotoxicity assay for anticancer-drug screening.J. Natl Cancer Inst.82(13), 1107–1112 (1990).
- Kalra AV , CampbellRB: Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: Implications for tumor vascular targeting.Pharm. Res.23(12), 2809–2817 (2006).
- Itakura J , IshiwataT, FriessHet al.: Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression.Clin. Cancer Res.3(8), 1309–1316 (1997).
- Niedergethmann M , HildenbrandR, WostbrockBet al.: High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas.Pancreas25(2), 122–129 (2002).
- Seo Y , BabaH, FukudaT, TakashimaM, SugimachiK: High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma.Cancer88(10), 2239–2245 (2000).
- Sun HC , QiuZJ, LiuJet al.: Expression of hypoxia-inducible factor-1α and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis.Int. J. Oncol.30(6), 1359–1367 (2007).
- Bockhorn M , TsuzukiY, XuL, FrillingA, BroelschCE, FukumuraD: Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts.Clin. Cancer Res.9(11), 4221–4226 (2003).